explore -WSS

explore

author：explore 2025-09-27 12:36:00 - browse：9

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： What it’s like to watch children die of measles

WSS

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

How to use technology to prevent future drug shortages

In same hospitals, Black patients receive fewer opioids than white patients

A deep dive into Applied Therapeutics’ data, and questions on Cassava

CDC marks new Covid

What it’s like to watch children die of measles

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Medicare proposal to cover medical devices draws a mixed reaction

Headspace, Meta partner to launch VR meditation app for Quest

Bright Health sells Medicare Advantage business to Molina

Drastic changes should bring profitability, startup health insurers say

Moonlake's readout produced a cash windfall. Risks remain

Maui's cultural, historic landmarks damaged in the devastating wildfires

explore

Just how do doctors, lawmakers, and the public define abortion?

Naloxone nonprofit donates 200,000 doses after FDA approval

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The best solution to the drug shortages problem

Change Healthcare payments predicted restored March 15

Change Healthcare cyberattack prompts Medicare loan program

knowledge

knowledge

leisure time

hotspot